Latest Articles

Publication Date
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - Yahoo Finance

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Yahoo Finance

Published: Feb. 27, 2025, 9:05 p.m.
Karyopharm Therapeutics Inc. SEC 10-K Report - TradingView

Karyopharm Therapeutics Inc. SEC 10-K Report TradingView

Published: Feb. 19, 2025, 12:38 p.m.
Real world perspectives on endometriosis disease phenotyping through surgery, omics, health data, and artificial intelligence.

Endometriosis is an enigmatic disease whose diagnosis and management are being transformed through innovative surgical, molecular, and computational technologies. Integrating single-cell and other omic disease data with clinical and surgical …

Published: Feb. 6, 2025, midnight
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire

Acrivon Therapeutics Announces FDA has Granted Breakthrough GlobeNewswire

Published: Feb. 5, 2025, 1:19 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times

Published: Feb. 5, 2025, 1:07 p.m.
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - MSN

Repare Therapeutics eyes Phase III cancer study after Mythic trial success MSN

Published: Jan. 14, 2025, 11:17 a.m.
Engineering nanosystems for regulating reproductive health in women.

Reproductive health-related diseases have a significant impact on the well-being of millions of women worldwide, severely compromising their quality of life. Women encounter unique challenges in terms of reproductive health, …

Published: Jan. 1, 2025, midnight
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - Yahoo Finance

Repare Therapeutics eyes Phase III cancer study after Mythic trial success Yahoo Finance

Published: Dec. 13, 2024, 3:28 p.m.
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial CRISPR Medicine News

Published: Dec. 13, 2024, 12:56 p.m.
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - BioSpace

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial BioSpace

Published: Dec. 12, 2024, 11:25 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!